LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.
Weekly Dose: A Roundup of Top Stories for Primary Care Physicians
PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.
Immunogenicity of Combined Flu/COVID-19 Vaccine Noninferior to Components in Older Adults
The investigational mRNA-1083 vaccine induced superior immune responses against all 4 flu strains in adults aged 50-64 years and against 3 in adults 65 and older.
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma
The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.
Rising Lp(a) Levels Increase Risk of Subsequent CVD Events in Adults with ASCVD, According to Large Real-World Study
Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.
